BICX

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 10

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,511,940

F10 · kind: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 9

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,498,782

F9 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.

SEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 4

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 843,578

F5 · kind: These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 8

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,454,922

F8 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 7

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,399,428

F7 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 6

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,343,872

F6 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 5

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,238,654

F5 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 4

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,223,029

F4 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.

SEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 3

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 830,420

F4 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 3

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,170,944

F3 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,115,385

F2 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193.

SEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 2

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 814,795

F2 · kind: These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange.

F3 · kind: These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation.

SEC source: 0001477932-24-004105 · form4.xml · nonDerivative · entry 2

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,191

F2 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.

SEC source: 0001477932-24-004103 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,599

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.

SEC source: 0001477932-24-004156 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 622,816

F2 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.

SEC source: 0001477932-24-004156 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 588,800

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock par value $0.001 per share (the "Common Stock") equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.

SEC source: 0001477932-24-003436 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 578,596

F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.73.

SEC source: 0001477932-24-002476 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,765

F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.77.

SEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,083,293

F1 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance.

SEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314,795

F1 · kind: These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance.

SEC source: 0001477932-24-001822 · form4.xml · nonDerivative · entry 2

Murthy Harsha · CIK 0001962250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,719

F2 · kind: These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-001832 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,698

Underlying: Common Stock · 16,698 shares

Expires 2029-03-28

F1 · shares: On March 28, 2024, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-24-001820 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 534,213

F2 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-001820 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,660

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock par value $0.001 per share (the "Common Stock") equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-001806 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,395

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-001895 · form4.xml · nonDerivative · entry 2

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,858

F2 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-004105 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,987

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.

SEC source: 0001477932-24-001093 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 510,094

F2 · kind: These shares were issued to Mr. Lucido pursuant to the Agreement. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares of Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.98.

SEC source: 0001477932-24-001093 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 493,202

F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.80.

SEC source: 0001477932-24-000249 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · Interim President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474,933

SEC source: 0001477932-24-000249 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · Interim President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474,807

SEC source: 0001477932-24-000035 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,421

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.

SEC source: 0001477932-24-000043 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,829

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.

SEC source: 0001477932-24-000042 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,519

Underlying: Common Stock · 18,519 shares

Expires 2029-01-02

F1 · shares: On January 2, 2024, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-24-000037 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 471,807

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.

SEC source: 0001477932-24-001822 · form4.xml · nonDerivative · entry 1

Murthy Harsha · CIK 0001962250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,153

F1 · kind: These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.

SEC source: 0001477932-24-001895 · form4.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,292

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.

SEC source: 0001477932-23-007297 · primary_doc.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,248

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-007298 · primary_doc.xml · nonDerivative · entry 1

Murthy Harsha · CIK 0001962250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,980

F1 · kind: These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-007296 · primary_doc.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 465,634

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-007295 · primary_doc.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,574

Underlying: Common Stock · 8,574 shares

Expires 2028-09-29

F1 · shares: On September 29, 2023, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-23-007294 · primary_doc.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,656

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-007335 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,065

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-007312 · primary_doc.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,119

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75.

SEC source: 0001477932-23-005018 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,390

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.

SEC source: 0001477932-23-005021 · form4.xml · nonDerivative · entry 2

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,207

F2 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.

SEC source: 0001477932-23-005020 · form4.xml · nonDerivative · entry 1

Murthy Harsha · CIK 0001962250 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,122

F1 · kind: These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.

SEC source: 0001477932-23-005019 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,673

Underlying: Common Stock · 8,673 shares

Expires 2028-06-30

F1 · shares: On June 30, 2023, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-23-005016 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,798

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.

SEC source: 0001477932-23-005017 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 462,776

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.